Hubei Jumpcan Pharmaceutical Valuation

Q: What is the Fair Price of 600566 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

600566 (CN¥26.58) is trading below our estimate of [[fair value]] (CN¥47.98)

Is 600566 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 600566 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 600566 (CN¥26.58) is trading below our estimate of fair value (CN¥47.98)

Significantly Below Fair Value: 600566 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 600566?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 600566. This is calculated by dividing 600566's market cap by their current preferred multiple.
What is 600566's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	CN¥24.50b

600566 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.6x
Enterprise Value/EBITDA	4.7x
PEG Ratio	0.8x

Price to Earnings Ratio vs Peers

How does 600566's PE Ratio compare to its peers?

The above table shows the PE ratio for 600566 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	59.3x
002262 Jiangsu Nhwa Pharmaceutical	23.1x	19.1%	CN¥25.9b
600521 Zhejiang Huahai Pharmaceutical	23.4x	24.6%	CN¥23.7b
600518 Kangmei Pharmaceutical	99.9x	n/a	CN¥24.4b
002603 Shijiazhuang Yiling Pharmaceutical	90.8x	41.7%	CN¥25.1b
600566 Hubei Jumpcan Pharmaceutical	8.7x	11.5%	CN¥24.5b

Price-To-Earnings vs Peers: 600566 is good value based on its Price-To-Earnings Ratio (8.7x) compared to the peer average (59.3x).

Price to Earnings Ratio vs Industry

How does 600566's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	19.4%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	19.4%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: 600566 is good value based on its Price-To-Earnings Ratio (8.7x) compared to the CN Pharmaceuticals industry average (25.4x).

Price to Earnings Ratio vs Fair Ratio

What is 600566's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

600566 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	8.7x
Fair PE Ratio	22.9x

Price-To-Earnings vs Fair Ratio: 600566 is good value based on its Price-To-Earnings Ratio (8.7x) compared to the estimated Fair Price-To-Earnings Ratio (22.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.